Context Therapeutics Acquires CT-95 for Cancer Trial Launch

Context Therapeutics (CNTX) has issued an announcement.

Context Therapeutics Inc. has acquired a promising cancer treatment drug, CT-95, from Link’s asset management company, with plans to launch a Phase 1 trial in early 2025. The acquisition includes patents, know-how, and materials necessary for the drug’s development, which the company will fund using existing cash reserves. In exchange for these assets, the company paid the seller $3.75 million. The transaction, which includes customary terms and confidentiality obligations, was publicly announced the day after the deal closed.

For a thorough assessment of CNTX stock, go to TipRanks’ Stock Analysis page.